HEG Limited is undergoing a transformative restructuring through a Composite Scheme of Arrangement that will split the company into two focused entities. The National Company Law Tribunal (NCLT) approved the demerger in August 2026, creating HEG Limited (formerly HEG Graphite Limited) for the graphite electrode business and HEG Greentech Limited for clean technology ventures. Shareholders will receive shares in both entities on a 1:1 mirror basis, maintaining identical ownership across the new structure. Others +1
The primary objective is to unlock shareholder value as the graphite electrode and green technology businesses command different market multiples. The fair valuation of the demerged green tech business is estimated at approximately ₹3,200 crores, suggesting the current market capitalization does not reflect the fair value of all diverse business lines. The graphite electrode business, with 100,000 TPA capacity expanding to 115,000 TPA by early 2028, is positioned as a global cost leader to capture the Electric Arc Furnace super-cycle. Meanwhile, HEG Greentech will house TACC Limited for advanced battery materials, Bhilwara Energy Limited with 300 MW hydroelectric power assets, and RePlus for battery storage solutions. Transcripts +3
The strategic benefits include focused management for each entity, independent capital access based on specific requirements, and clearer investment theses for distinct business profiles. HEG Greentech starts with zero net debt, supported by ₹500 crore strategic investment from Singularity and robust annual free cash flows of ₹320-350 crores from hydropower. However, execution risks include regulatory delays, maintaining synergies between separated businesses, and market acceptance of the new structure. The company aims for 4-digit EBITDA by 2030 across all businesses combined. Others +4
ESDS Software Solution delivered an exceptional listing performance, surging 154.09% from its IPO issue price of ₹429 to ₹1,090.05 by the second trading day and hitting the 20% upper circuit. The IPO was subscribed 142.88 times overall, with massive institutional demand driving the premium valuation. Qualified Institutional Buyers subscribed 274.97 times, Non-Institutional Investors 202.87 times, and retail investors 41.68 times.
With 100% of proceeds going to the company for business expansion rather than promoter exits, the market could focus purely on growth fundamentals. This structure reduced downside pressure from lock-in expiry overhangs and limited supply pressure from existing shareholders. The company's strong financial metrics supported the premium valuation, with revenue growing from ₹2,865.18 crore in FY2024 to ₹4,722.10 crore in FY2026, and PAT margins expanding from 15.39% in FY2025 to 25.59% in FY2026. RHP +1
ESDS offers comprehensive cloud infrastructure and software solutions, with proprietary SWARAJ vertical autoscaling cloud technology patented in the US and India. The company operates five Data Centres in India and launched fully managed GPUaaS in November 2025. The ₹576 crore raised from the IPO will fund cloud computing and data centre infrastructure expansion. The strong grey market premium of ₹230-255 (54-59% listing gains) was exceeded by actual listing performance of 76.46%, demonstrating stronger-than-anticipated market appetite for AI-enabled cloud services. RHP +2
Maruti Suzuki faces significant margin pressure from sustained input cost inflation, with material costs increasing 600 bps YoY in Q1 FY27 and 380 bps sequentially. The company has implemented calibrated price increases of up to ₹30,000 across its portfolio in June and August 2026 to protect margins. However, the effectiveness of these price increases is constrained by demand elasticity, particularly in price-sensitive entry-level segments like the Alto K10 and S-Presso. InvestorPresentations +1
The company's margin protection strategy combines pricing power with comprehensive cost reduction measures. Maruti has saved approximately ₹175 crore over three fiscals through value engineering initiatives. The flagship 'Sujhav Sangrehika' employee suggestion scheme generated the highest-ever cost savings of ₹769 crore in FY 2023-24. Yield improvement projects reduced steel consumption by over 5,000 MT in FY 2024-25. The company is also aggressively localizing components to reduce import dependency, with 94% of Tier-1 suppliers based in India and 87% within 100 km of manufacturing facilities. AnnualReports +2
Operational efficiency initiatives include high capacity utilization, which management emphasizes "helps a lot with margins". Green logistics efficiency has improved, with railway dispatches growing from 5.1% of outbound logistics in 2016 to 26.5% in FY 2025-26. Energy conservation initiatives saved approximately 2.6 million kWh annually. Despite these measures, the company faces challenges from geopolitical headwinds affecting commodity prices, with management confident of returning to a "healthy trajectory" once these subside. The long-term target remains achieving 10% EBIT margin by 2030. Transcripts +5
Zydus Wellness has delivered strong 18.52% year-to-date performance despite broader market headwinds from elevated crude oil prices. IIFL Capital's positive coverage initiation with a "buy" rating and ₹650 target price (23% upside) catalyzed valuation re-rating and stock momentum. The brokerage noted that Zydus Wellness is "a structurally different company" with acquired growth engines reducing sensitivity to seasonal and mature categories.
The company's fundamental growth drivers are robust. FY26 results showed 46.2% revenue growth to ₹36,610 million and 34.2% EBITDA growth to ₹5,097 million. International business, including the newly acquired Comfort Click, contributes more than 30% of total revenue. The company has achieved significant margin improvements, with management targeting 17-18% EBITDA margins over the next 2 years. Digital transformation has driven organized channel saliency to 30% in FY26 from 24% in FY25. Transcripts +1
Brand portfolio performance remains strong across categories. Sugar Free portfolio delivered double-digit growth, significantly outperforming category trends. Sugar Free Green achieved 21st consecutive quarter of double-digit growth. Everyuth and Nycil delivered consistent double-digit 3-year CAGR, growing faster than the market. Max Protein (RiteBite) achieved nearly 50% growth, reaching approximately ₹244 crores in revenue. The company's resilience against crude oil headwinds stems from premium positioning, strong brand equity allowing calibrated price increases, and ~55% gross margins providing buffer against cost inflation. InvestorPresentations +3
Novartis India made a strategic move to acquire the Minipress and Minipres trademarks from Pfizer for ₹1,250 crore, significantly enhancing its cardiovascular and urology portfolio. The acquisition includes Minipress XL (prazosin), which generated ₹228.6 crore revenue in FY26 with a 6.3% CAGR over the past four years. The 5.5x revenue multiple suggests Novartis is paying for long-term market share stability and brand equity rather than immediate cash flow generation.
Minipress XL is primarily indicated for treating hypertension and managing urinary symptoms associated with benign prostatic hyperplasia (BPH). The acquisition strengthens Novartis India's position in the established cardiovascular and urology medicine segment. The Indian hypertension drug market grew at 6.9% CAGR from 2016-2018, reaching INR 87.36 billion in value. The global BPH treatment market is projected to reach USD 21.27 billion by 2034, growing at 5.50% CAGR, with alpha-blockers dominating the market in 2022.
The strategic rationale includes portfolio enhancement, therapeutic synergy with existing cardiovascular offerings, and leveraging Novartis's superior marketing capabilities and distribution network. Revenue enhancement strategies include enhanced marketing, distribution expansion, physician relationship utilization, and strategic positioning within comprehensive cardiovascular solutions. While Minipress XL has underperformed the broader hypertension market's 9% CAGR, Novartis's operational excellence could accelerate growth. The acquisition represents a significant investment for Novartis India, but its strong financial position with minimal debt and strong liquidity provides the capacity to execute this strategic acquisition effectively.
The divergent performance across sectors during the recent NIFTY50 and SENSEX decline highlights varying impacts of elevated crude oil prices and US interest rate hike concerns. Maruti Suzuki faces significant cost structure pressures from crude oil through input costs and logistics, while Zydus Wellness and Novartis India demonstrate greater resilience due to inelastic healthcare demand.
Crude oil prices influence FMCG costs through multiple channels. Packaging materials derived from crude-linked petrochemicals account for 12-18% of cost of goods sold, while logistics make up 6-8% of sales. For diversified FMCG firms, direct crude-linked exposure is estimated at 8-12% of total cost base. A sustained spike in crude could compress EBITDA margins by 80-120 basis points if companies choose to absorb costs. However, pharmaceutical companies like Novartis India have limited direct exposure to crude-derived inputs and benefit from inelastic demand for essential medicines.
US interest rate hike concerns have disproportionately impacted technology stocks. The Nifty IT index has fallen approximately 26% year-to-date, with Infosys, HCLTech, Wipro, and TCS all experiencing significant declines. Higher discount rates reduce the present value of future cash flows for growth companies, while US enterprise technology budgets tighten with rate hikes. In contrast, defensive sectors like healthcare (Apollo Hospitals, Max Healthcare) and utilities (Power Grid) have outperformed due to stable demand and regulated returns. Healthcare demand is relatively inelastic to economic cycles, while utilities offer predictable returns through regulatory frameworks and high dividend yields.
This sector rotation reflects investors' preference for stability and predictable cash flows during periods of economic uncertainty and market volatility. Companies with strong balance sheets, pricing power, and essential business models are better positioned to navigate the current challenging environment, while cyclical sectors may continue to face headwinds until economic conditions improve.
